Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roche Holding AG Basel American Depositary Shares (OP: RHHBY ) 41.50 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Roche Holding AG Basel American Depositary Shares < Previous 1 2 3 4 5 6 7 8 9 ... 21 22 Next > Ignore Crypto: These Stocks Could Make You Rich November 23, 2023 Investing in solid, growing businesses is a less risky road to riches than investing in Bitcoin or other cryptocurrencies. Via The Motley Fool Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare November 17, 2023 Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare. Via InvestorPlace FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca November 16, 2023 The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small Via Benzinga Exposures Product Safety The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks? November 10, 2023 The real competitive battle is about to begin, and it will last a long time. Via The Motley Fool BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake November 07, 2023 The company's recently FDA-approved gene therapy is struggling to gain traction. Via Investor's Business Daily Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug November 02, 2023 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate Via Benzinga Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks October 31, 2023 Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)... Via Benzinga Exposures Product Safety Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More October 28, 2023 The U.S. Via Benzinga Exposures Product Safety Roche, Lilly or Pfizer: Who's the Winner in IBD Wars? October 28, 2023 The three companies are spending big on IBD therapies. Via The Motley Fool It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy October 24, 2023 The market's dour reaction to Roivant Sciences' latest deal doesn't add up. Via The Motley Fool Why Is Roivant Sciences (ROIV) Stock Up Today? October 23, 2023 ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates. Via InvestorPlace Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space October 23, 2023 Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. Via Investor's Business Daily Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal October 23, 2023 Roche Holding AG (OTC: RHHBY) inked a deal to acquire Via Benzinga Which Is the Better Long-Term Hold for Investors: Pfizer or Roche? October 21, 2023 The venerable pharmaceutical companies' shares have slumped this year. Via The Motley Fool Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance October 19, 2023 The company's third-quarter sales also declined and came in light. Via Investor's Business Daily Exposures COVID-19 Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products October 19, 2023 Roche Holdings AG's (OTC: RHHBY) nine months Via Benzinga Exposures COVID-19 What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? October 17, 2023 Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC: Via Benzinga FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication October 17, 2023 The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing... Via Benzinga Exposures Product Safety Why Is Alzheimer's Player Prothena Stock Trading Higher Today? October 16, 2023 Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale. Via Benzinga AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points October 14, 2023 Broadcom and Arista lead five stocks sporting a flat base. Via Investor's Business Daily Topics Artificial Intelligence Exposures Artificial Intelligence TPST Stock: 7 Things to Know About Tempest Therapeutics October 11, 2023 Are you curious about the recent surge from Tempest Therapeutics? Here's a closer look at this company and at TPST stock. Via InvestorPlace Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready October 11, 2023 Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... Via Benzinga Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update October 04, 2023 Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c Via Benzinga Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich October 03, 2023 Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich. Via InvestorPlace 2 Cathie Wood Stocks That Could Deliver Exponential Returns October 02, 2023 These two cutting-edge healthcare companies could be significantly undervalued right now. Via The Motley Fool Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges September 27, 2023 Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY Via Benzinga Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder September 26, 2023 IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder. Via Investor's Business Daily AI To Revolutionize Clinical Trials And Diagnostics September 22, 2023 With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year September 21, 2023 In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. Via Benzinga Exposures COVID-19 Buy List Alert: 3 Pharma Stocks with Positive Trial Updates September 13, 2023 These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 ... 21 22 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.